KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Asset Writedowns and Impairment (2020 - 2025)

Boston Scientific's Asset Writedowns and Impairment history spans 6 years, with the latest figure at $42.0 million for Q4 2024.

  • For Q4 2024, Asset Writedowns and Impairment rose 235.48% year-over-year to $42.0 million; the TTM value through Dec 2025 reached -$204.0 million, up 12.82%, while the annual FY2025 figure was $46.0 million, 36.11% down from the prior year.
  • Asset Writedowns and Impairment for Q4 2024 was $42.0 million at Boston Scientific, up from -$246.0 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $219.0 million in Q3 2020 and bottomed at -$246.0 million in Q3 2024.
  • The 5-year median for Asset Writedowns and Impairment is $65.0 million (2020), against an average of $66.2 million.
  • The largest YoY upside for Asset Writedowns and Impairment was 235.48% in 2024 against a maximum downside of 24700.0% in 2024.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $81.0 million in 2020, then surged by 143.21% to $197.0 million in 2021, then tumbled by 36.55% to $125.0 million in 2022, then plummeted by 124.8% to -$31.0 million in 2023, then surged by 235.48% to $42.0 million in 2024.
  • Per Business Quant, the three most recent readings for BSX's Asset Writedowns and Impairment are $42.0 million (Q4 2024), -$246.0 million (Q3 2024), and -$31.0 million (Q4 2023).